Fesko John sold $440K of NTRA

Fesko John (PRESIDENT, CHIEF BUS. OFFICER) sold 1,713 shares of Natera, Inc. (NTRA) at an average of $257.00 ($254.07–$260.49, $0.44M total) across 2 trades over 2026-07-27 to 2026-07-28 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Fesko John
Published Jul 30, 2026, 1:35 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 30, 2026, 2:01 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$NTRA
Neutral
high confidence
Mentioned
$NTRA
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRANeutralLow
01

Why it matters

The disclosure provides transparency on executive share sales but does not introduce new company-specific catalysts like earnings, guidance, trials, deals, or regulatory actions.

02

Market read

For NTRA, this is primarily a sentiment datapoint rather than a fundamental driver.

03

What to watch

Traders may over-weight insider selling; the key incremental data here is only the disclosed sale size and timing, not any change in guidance or business performance.

Relevance 3/10Novelty 3/10Timing: after-hours SEC Form 4 filing dated 2026-07-29 for sales on 2026-07-27 to 2026-07-28

Background

The article is an SEC Form 4 insider transaction disclosure for Natera, Inc.

Company-level read

Ticker impact

$NTRANeutralHigh confidence
Context

Natera insider Form 4 shows President/COO Fesko John sold about 1,713 shares for roughly $440K under a 10b5-1 plan.

Expected impact

Likely minimal, with any effect confined to short-term sentiment rather than a fundamental repricing.

Evidence & confidence

The filing is a disclosed insider transaction, but it is explicitly pre-arranged under Rule 10b5-1 and does not include new operating, financial, or regulatory information.

Market effects

No clear read-across to the broader biotech/diagnostics sector from a single routine 10b5-1 sale.

None.

None.

Counterpoint

Because the sale is under a pre-arranged 10b5-1 plan, it may reflect liquidity planning rather than bearish expectations.

Key entities

  • Natera, Inc.

    Company whose insider transaction is disclosed on Form 4.

  • Fesko John

    President and Chief Business Officer who sold shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NTRAMed

What's Next for Colorectal Cancer? A Major Announcement at OncoDaily

Natera announced a partnership with Agenus to use Signatera ctDNA testing in the Phase III ROBIN trial for colorectal cancer. The trial will compare neoadjuvant immunotherapy plus surgery to upfront surgery. Dr. Robert Lentz, Natera's Medical Director, highlighted the potential of ctDNA testing in treatment evaluation and decision-making.

$NTRAMed

Natera CFO Defends CEO Switch, Calls $6 Billion Revenue Target a “Way Station”

Natera CFO David Brophy defended the CEO transition and outlined long-term revenue targets. He estimated a $20B-$40B market opportunity for Signatera, with $1B revenue expected this year. Brophy also discussed competition, pricing, and market expansion into colorectal cancer screening and early detection tests. Natera (NASDAQ:NTRA) develops genetic testing and molecular diagnostics for various health applications.

$NTRAMed

Natera, Incyte Launch Phase 2 MRD-Guided Colorectal Cancer Study

Natera (NTRA) and Incyte (INCY) launched a Phase 2 study for colorectal cancer using Natera's Signatera test to identify high-risk patients. The trial will evaluate Incyte's INCA33890 immunotherapy in stage 2 or 3 patients post-treatment. Signatera will monitor patients for up to 12 months, with MRD-positive patients potentially enrolling. The study aims to improve outcomes by intervening earlier. NTRA closed at $320.39, up 3.13%.